Posted by Michael Wonder on 19 Mar 2021
Janssen announces U.S. FDA approval of Ponvory (ponesimod), an oral treatment for adults with relapsing multiple sclerosis proven superior to Aubagio (teriflunomide) in reducing annual relapses and brain lesions
19 March 2021 - Ponvory is the first and only FDA approved oral disease modifying therapy studied against an established oral comparator.
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. FDA approved Ponvory (ponesimod), a once daily oral selective sphingosine-1-phosphate receptor 1 modulator, to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
